Third oral agent for ED wins FDA approval

The FDA has approved tadalafil (Cialis), a new oral PDE-5 inhibitor, for the treatment of erectile dysfunction.

Related Content:

Drug Therapy

Pivotal data for lumasiran in PH1 published in NEJM

Nedosiran explored in primary hyperoxaluria type 3

Enrollment completed in pivotal trial of nedosiran for hyperoxaluria